Sphingosine Kinases and Sphingosine 1-Phosphate Receptors: Signaling and Actions in the Cardiovascular System.
Sphingosine Kinases and Sphingosine 1-Phosphate Receptors: Signaling and Actions in the Cardiovascular System.
复制标题
鞘氨醇激酶和1-磷酸盐受体:心血管系统中的信号传导和作用。
DOI:
10.3389/fphar.2017.00556
复制
发表时间:
2017
影响因子:
5.6
通讯作者:
Rengo G
中科院分区:
文献类型:
--
作者:
Cannavo A;Liccardo D;Komici K;Corbi G;de Lucia C;Femminella GD;Elia A;Bencivenga L;Ferrara N;Koch WJ;Paolocci N;Rengo G
The sphingosine kinases 1 and 2 (SphK1 and 2) catalyze the phosphorylation of the lipid, sphingosine, generating the signal transmitter, sphingosine 1-phosphate (S1P). The activation of such kinases and the subsequent S1P generation and secretion in the blood serum of mammals represent a major checkpoint in many cellular signaling cascades. In fact, activating the SphK/S1P system is critical for cell motility and proliferation, cytoskeletal organization, cell growth, survival, and response to stress. In the cardiovascular system, the physiological effects of S1P intervene through the binding and activation of a family of five highly selective G protein-coupled receptors, called S1PR1-5. Importantly, SphK/S1P signal is present on both vascular and myocardial cells. S1P is a well-recognized survival factor in many tissues. Therefore, it is not surprising that the last two decades have seen a flourishing of interest and investigative efforts directed to obtain additional mechanistic insights into the signaling, as well as the biological activity of this phospholipid, and of its receptors, especially in the cardiovascular system. Here, we will provide an up-to-date account on the structure and function of sphingosine kinases, discussing the generation, release, and function of S1P. Keeping the bull’s eye on the cardiovascular system, we will review the structure and signaling cascades and biological actions emanating from the stimulation of different S1P receptors. We will end this article with a summary of the most recent, experimental and clinical observations targeting S1PRs and SphKs as possible new therapeutic avenues for cardiovascular disorders, such as heart failure.
登录
查看更多内容
影响因子:
4.5
作者:
Argraves KM;Sethi AA;Gazzolo PJ;Wilkerson BA;Remaley AT;Tybjaerg-Hansen A;Nordestgaard BG;Yeatts SD;Nicholas KS;Barth JL;Argraves WS
通讯作者:
Argraves WS
影响因子:
16.6
作者:
Cannavo A;Liccardo D;Eguchi A;Elliott KJ;Traynham CJ;Ibetti J;Eguchi S;Leosco D;Ferrara N;Rengo G;Koch WJ
通讯作者:
Koch WJ
影响因子:
64.5
作者:
Chipuk JE;McStay GP;Bharti A;Kuwana T;Clarke CJ;Siskind LJ;Obeid LM;Green DR
通讯作者:
Green DR
DOI:
10.1124/jpet.115.228411
发表时间:
2016-02-01
影响因子:
3.5
作者:
Cannavo, Alessandro;Liccardo, Daniela;Rengo, Giuseppe
通讯作者:
Rengo, Giuseppe
DOI:
10.1124/jpet.107.133975
发表时间:
2008-03-01
影响因子:
3.5
作者:
Errami, Mounir;Galindo, Cristi L.;Garner, Harold R.
通讯作者:
Garner, Harold R.